Tadao Akizawa

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 39

Top Topics

Peritoneal Dialysis

Chronic Kidney Disease

Cardiovascular Events

Top Venues

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

Clinical and experimental nephrology

Advances in therapy

Patient preference and adherence

This page only lists publications with an associated author ORCID identifier.

Publications

Kyoko Ito, Tadao Akizawa, Kojo Arita, Yuko Mitobe, Norio Komatsu
Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. Clinical and experimental nephrology 28 (7) (2024)
Kyoko Ito, Tadao Akizawa, Kojo Arita, Yuko Mitobe, Norio Komatsu
Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. Clinical and experimental nephrology 28 (7) (2024)
Kyoko Ito, Tadao Akizawa, Kojo Arita, Yuko Mitobe, Norio Komatsu
Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. Clinical and experimental nephrology 28 (7) (2024)
Sari Mishina, Yuichiro Ito, Takumi Lee, Toshiaki Murofushi, Yoshiyuki Uetake, Tadao Akizawa
Physician and Patient Preferences for Treatment of Anemia Associated with Chronic Kidney Disease in Japan: A Survey Including Best-Worst Scaling. Patient preference and adherence 18 (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Shaka Martin, Alina Jiletcovici, Frank Dellanna, Tadao Akizawa, Jonathan Barratt
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials. Advances in therapy (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Sho Mizokawa, Yuichiro Ito, Frank Dellanna, Jonathan Barratt, Tadao Akizawa
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan. Advances in therapy 41 (4) (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Shaka Martin, Alina Jiletcovici, Frank Dellanna, Tadao Akizawa, Jonathan Barratt
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials. Advances in therapy 41 (4) (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Sho Mizokawa, Yuichiro Ito, Frank Dellanna, Jonathan Barratt, Tadao Akizawa
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan. Advances in therapy (2024)
Kyoko Ito, Tadao Akizawa, Kojo Arita, Yuko Mitobe, Norio Komatsu
Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. Clinical and experimental nephrology (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Shaka Martin, Alina Jiletcovici, Frank Dellanna, Tadao Akizawa, Jonathan Barratt
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials. Advances in therapy 41 (4) (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Sho Mizokawa, Yuichiro Ito, Frank Dellanna, Jonathan Barratt, Tadao Akizawa
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan. Advances in therapy 41 (4) (2024)
Kyoko Ito, Tadao Akizawa, Kojo Arita, Yuko Mitobe, Norio Komatsu
Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. Clinical and experimental nephrology (2024)
Masanori Kato, Hidetoshi Ito, Akane Yamakawa, Tatsuo Kagimura, Masafumi Fukagawa, Masahiro Yamamoto, Yoshinori Saito, Tadao Akizawa, Hiroaki Ogata
Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 28 (4) (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Sho Mizokawa, Yuichiro Ito, Frank Dellanna, Jonathan Barratt, Tadao Akizawa
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan. Advances in therapy 41 (4) (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Sho Mizokawa, Yuichiro Ito, Frank Dellanna, Jonathan Barratt, Tadao Akizawa
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan. Advances in therapy 41 (4) (2024)
Sari Mishina, Yuichiro Ito, Takumi Lee, Toshiaki Murofushi, Yoshiyuki Uetake, Tadao Akizawa
Physician and Patient Preferences for Treatment of Anemia Associated with Chronic Kidney Disease in Japan: A Survey Including Best-Worst Scaling. Patient preference and adherence 18 (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Shaka Martin, Alina Jiletcovici, Frank Dellanna, Tadao Akizawa, Jonathan Barratt
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials. Advances in therapy 41 (4) (2024)
Takayuki Hamano, Yusuke Yamaguchi, Kashia Goto, Shaka Martin, Alina Jiletcovici, Frank Dellanna, Tadao Akizawa, Jonathan Barratt
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials. Advances in therapy 41 (4) (2024)
Masanori Kato, Hidetoshi Ito, Akane Yamakawa, Tatsuo Kagimura, Masafumi Fukagawa, Masahiro Yamamoto, Yoshinori Saito, Tadao Akizawa, Hiroaki Ogata
Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2024)
Kyoko Ito, Tadao Akizawa, Kojo Arita, Yuko Mitobe, Norio Komatsu
Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. Clinical and experimental nephrology 28 (7) (2024)
Hiroyasu Yamamoto, Takashi Yamada, Ken Miyazaki, Takuto Yamashita, Takuya Kato, Kenichi Ohara, Yusuke Nakamura, Tadao Akizawa
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Clinical and experimental nephrology (2023)
Hiroyasu Yamamoto, Takashi Yamada, Ken Miyazaki, Takuto Yamashita, Takuya Kato, Kenichi Ohara, Yusuke Nakamura, Tadao Akizawa
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Clinical and experimental nephrology (2023)
Kan Kikuchi, Masaomi Nangaku, Munekazu Ryuzaki, Tomoyuki Yamakawa, Yoshihiro Ota, Norio Hanafusa, Ken Sakai, Yoshihiko Kanno, Ryoichi Ando, Toshio Shinoda, Shu Wakino, Hidetomo Nakamoto, Yoshiaki Takemoto, Tadao Akizawa, null null
Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2023)
Takashi Shigematsu, Fumihiko Koiwa, Yoshitaka Isaka, Masafumi Fukagawa, Keiko Hagita, Yukihisa S Watanabe, Daisuke Honda, Tadao Akizawa
Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial. Clinical journal of the American Society of Nephrology : CJASN (2023)
Kazuaki Ikejiri, Takafumi Suzuki, Satsuki Muto, Hirotaka Takama, Kengo Yamawaki, Tatsuya Miyazawa, Itaru Urakawa, Yuichi Aoki, Akihito Otsuki, Fumiki Katsuoka, Kengo Kinoshita, Masaomi Nangaku, Tadao Akizawa, Masayuki Yamamoto
Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study. Clinical and experimental nephrology (2023)
Hiroyasu Yamamoto, Takashi Yamada, Ken Miyazaki, Takuto Yamashita, Takuya Kato, Kenichi Ohara, Yusuke Nakamura, Tadao Akizawa
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Clinical and experimental nephrology (2023)
Yoshinori Saito, Hidetoshi Ito, Masafumi Fukagawa, Tadao Akizawa, Tatsuo Kagimura, Masahiro Yamamoto, Masanori Kato, Hiroaki Ogata
Effect of renin-angiotensin system inhibitors on cardiovascular events in hemodialysis patients with hyperphosphatemia: A post hoc analysis of the LANDMARK trial. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2023)
Ryo Fujikawa, Yuji Nagao, Masaki Fujioka, Tadao Akizawa
Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 26 (4) (2022)
Kan Kikuchi, Masaomi Nangaku, Munekazu Ryuzaki, Tomoyuki Yamakawa, Ota Yoshihiro, Norio Hanafusa, Ken Sakai, Yoshihiko Kanno, Ryoichi Ando, Toshio Shinoda, Shu Wakino, Hidetomo Nakamoto, Yoshiaki Takemoto, Tadao Akizawa, null null
Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: A nationwide cohort study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2022)
Masaomi Nangaku, Tadao Akizawa, Takashi Nagakubo, Taeko Yonekawa, Toshifumi Kimura, Yukihiro Endo, Alexander Cobitz
Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 26 (6) (2022)
Tadao Akizawa
Appreciation for the contribution of the Japanese Society for Dialysis Therapy to development of Therapeutic Apheresis and Dialysis. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 25 (6) (2022)
Kiryu Yoshida, Takuya Mizukami, Masafumi Fukagawa, Tadao Akizawa, Hokuto Morohoshi, Takehiko Sambe, Akiko Takeshima, Hidetoshi Ito, Hiroaki Ogata, Naoki Uchida
Effect of vitamin D receptor activators on cardiovascular events in patients on hemodialysis-A post hoc analysis of the LANDMARK study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2022)
Tadao Akizawa, Kiyoshi Nobori, Yoshimi Matsuda, Yasuhiro Hayashi, Takanori Hayasaki, Hiroyasu Yamamoto
Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 25 (6) (2021)
Tadao Akizawa, Kiyoshi Nobori, Yoshimi Matsuda, Kentaro Taki, Yasuhiro Hayashi, Takanori Hayasaki, Hiroyasu Yamamoto
Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2021)
Tadao Akizawa, Masaomi Nangaku, Takuhiro Yamaguchi, Ryosuke Koretomo, Kazuo Maeda, Osamu Yamada, Hideki Hirakata
Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2021)
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa, Tadao Akizawa
Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis. International journal of nephrology and renovascular disease 13 (2020)
Tadao Akizawa, Tetsuro Otsuka, Michael Reusch, Mai Ueno
Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 24 (2) (2019)
Tadao Akizawa, Megumi Taguchi, Yoshimi Matsuda, Kazuma Iekushi, Takashi Yamada, Hiroyasu Yamamoto
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. BMJ open 9 (6) (2019)
Ryo Kido, Tadao Akizawa, Shunichi Fukuhara
Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS). BMJ open 9 (9) (2019)